Biolegend, 505832, Brilliant Violet 650™ anti-mouse IFN-γ Antibody
50microg
Catalog Number: 505832
Send an RFQ.
Category
Loading…
| Verified Reactivity | Mouse |
|---|---|
| Antibody Type | Monoclonal |
| Host Species | Rat |
| Immunogen | E. coli-expressed, recombinant mouse IFN-γ |
| Formulation | Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA). |
| Preparation | The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 650™ under optimal conditions. |
| Concentration | µg sizes: 0.2 mg/mLµL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.) |
| Storage & Handling | The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze. |
| Application | ICFC - Quality tested |
Unless otherwise stated, the minimum order amount is USD 1,000.
For orders below USD 1,000, an additional handling fee may apply, or we may arrange local delivery / local handover where available.
All quotations are subject to final confirmation, including product availability, lead time, batch information, shipping cost, and applicable export or handling requirements.
For quotation requests, please send an RFQ from website or contact:
Please send inquiries directly to us in the “To” field. Emails sent via BCC, mass mailing, or with unrelated recipients may be automatically filtered and will not be processed.
| Recommended Usage |
|---|
| Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining in µl size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. For flow cytometric staining in µg size, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application. Brilliant Violet 650™ excites at 405 nm and emits at 645 nm. The bandpass filter 660/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 650™ is a trademark of Sirigen Group Ltd. Learn more about Brilliant Violet™. This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents. |
| Excitation Laser | Violet Laser (405 nm) |
|---|
| Application Notes | ELISA1-4,11,14 or ELISPOT5 Detection: The biotinylated XMG1.2 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified R4-6A2 antibody (Cat. No. 505702/505706) as the capture antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard. ELISA or ELISPOT Capture: The purified XMG1.2 antibody is useful as a capture antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with biotinylated R4-6A2 antibody (Cat. No. 505704) as the detection antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard. The LEAF™ purified antibody is suggested for ELISPOT capture (Cat. No. 505812). Flow Cytometry7,8,12,13,16: The fluorochrome-labeled XMG1.2 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN-γ-producing cells within mixed cell populations. Neutralization1-3,9,10: The XMG1.2 antibody can neutralize the bioactivity of natural or recombinant IFN-γ. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse IFN-γ bioactivity in vivo and in vitro (Cat. No. 505812). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 505834) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg). Additional reported applications (for the relevant formats) include: Western blotting, immunohistochemical staining of frozen tissue sections6,22,23, and immunocytochemistry. Note: For testing mouse IFN-γ in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets (Cat. No. 430801 to 430806) are specially developed and recommended. |
|---|
| Application References(PubMed link indicates BioLegend citation) | Abrams J, et al. 1992. Immunol. Rev. 127:5. (ELISA, Neut) Sander B, et al. 1993. J. Immunol. Meth. 166:201. (ELISA, Neut) Abrams J, et al. 1995. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.20. (ELISA, Neut) Yang X, et al. 1993. J. Immunoassay 14:129. (ELISA) Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.19. (ELISPOT) Sander B, et al. 1991. Immunol. Rev. 119:65. (IHC) Ferrick D, et al. 1995. Nature 373:255. (FC) Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed Peterson KE, et al. 2000. J. Virol. 74:5363. (Neut) DeKrey GK, et al. 1998. Infect. Immun. 66:827. (Neut) Dzhagalov I, et al. 2007. J. Immunol. 178:2113. (ELISA) Lawson BR, et al. 2007. J. Immunol. 178:5366. (FC) Lee JW, et al. 2006. Nature Immunol. 8:181. (FC) PubMed Xu G, et al. 2007. J. Immunol. 179:5358. (ELISA) PubMed Montfort M, et al.2004. J. Immunol. 173:4084. PubMed Haring JS, et al. 2008. J. Immunol. 180:2855. (FC) PubMed Jordan JM, et al. 2008. Infect Immun. 76:3717. PubMed Tonkin DR, et al. 2008. J. Immunol. 181:4516. PubMed Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed Cui Y, et al. 2009. Invest. Ophth. Vis. Sci. 50:5811. (FC) PubMed Mykkanen OT, et al. 2014. PLoS One. 9:114790. PubMed Yokogawa M, et al. 2013. Mol. Carcinog. 52:760. (IHC) Mottram PL, et al. 1998. J Immunol. 161:602. (IHC) |
|---|
| Product Citations | Wu Z, et al. 2023. EMBO Rep. 24:e56524. PubMed Wu Y, et al. 2023. Nat Cancer. 4:382. PubMed Read KA, et al. 2023. Nat Commun. 14:1652. PubMed Riffelmacher T, et al. 2023. Nat Cell Biol. 25:877. PubMed Nesseler JP, et al. 2020. Cancers (Basel). 12: . PubMed Liu Z, et al. 2022. Cancer Commun (Lond). 42:971. PubMed Wang R, et al. 2023. NPJ Vaccines. 8:6. PubMed Yu Y, et al. 2022. iScience. 25:105004. PubMed Boothby IC, et al. 2021. Nature. 599:667. PubMed Glaubitz J, et al. 2022. Nat Commun. 13:4502. PubMed Dodagatta-Marri E, et al. 2021. Cell Rep. 36:109309. PubMed Willingham SB, et al. 2018. Cancer Immunol Res. 6:1136. PubMed Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed Kotov DI, et al. 2018. J Immunol. 200:2004. PubMed Sendler M, et al. 2020. Gastroenterology. 158:253. PubMed Montfort M, et al. 2004. J Immunol. 173:4084. PubMed Cabrera-Perez J, et al. 2016. J Immunol. 197: 1692 - 1698. PubMed Cabrera-Perez C, et al. 2015. J Immunol . 194:1609-20. PubMed Lee J, et al. 2007. Nat Immunol. 8:181. PubMed Chen Y, et al. 2022. Nat Commun. 13:4468. PubMed Loo Yau H, et al. 2021. Molecular Cell. 81(7):1469-1483.e8. PubMed Lederer K, et al. 2020. Immunity. 53(6):1281-1295.e5. PubMed Shen H, et al. 2022. Nat Commun. 13:5013. PubMed |
|---|
| RRID | AB_11142685 (BioLegend Cat. No. 505831) AB_2734492 (BioLegend Cat. No. 505832) |
|---|
| Structure | Cytokine; dimer; 40-80 kD (Mammalian) |
|---|
| Bioactivity | Antiviral/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APCs |
|---|
| Cell Sources | CD8+ and CD4+ T cells, NK cells |
|---|
| Cell Targets | T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts |
|---|
| Receptors | IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1) |
|---|
| Cell Type | Tregs |
|---|
| Biology Area | Cell Biology, Immunology, Neuroinflammation, Neuroscience |
|---|
| Molecular Family | Cytokines/Chemokines |
|---|
| Antigen References | 1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego. 2. De Maeyer E, et al. 1992. Curr. Opin. Immunol. 4:321. 3. Farrar M, et al. 1993. Annu. Rev. Immunol. 11:571. 4. Gray P, et al. 1987. Lymphokines 13:151. |
|---|
| Regulation | Upregulated by IL-2, FGF-basic, EGF; downregulated by 1-α-25-Dihydroxy vitamin D3, dexamethasone |
|---|
| Gene ID | 15978 |
|---|
| UniProt | View information about IFN-gamma on UniProt.org |
|---|
| Clone | XMG1.2 |
|---|
| Regulatory Status | RUO |
|---|
| Other Names | Interferon-γ, Immune interferon, Type II interferon, T cell interferon, Macrophage-activating factor (MAF) |
|---|
| Isotype | Rat IgG1, κ |
|---|
